Avalo Therapeutics (AVTX) Expected to Announce Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) is projected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Avalo Therapeutics to post earnings of ($0.5827) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. On average, analysts expect Avalo Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX opened at $18.53 on Wednesday. The company has a market capitalization of $980.24 million, a price-to-earnings ratio of -3.39 and a beta of 0.80. Avalo Therapeutics has a one year low of $7.87 and a one year high of $24.27. The stock has a 50-day simple moving average of $17.10 and a 200 day simple moving average of $16.22.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Leerink Partners began coverage on Avalo Therapeutics in a report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Citizens Jmp dropped their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Wedbush reduced their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Finally, Mizuho raised their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $45.80.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. This represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics in the second quarter worth $56,000. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics during the third quarter valued at $143,000. Jump Financial LLC acquired a new position in shares of Avalo Therapeutics during the fourth quarter valued at $238,000. Persistent Asset Partners Ltd bought a new position in shares of Avalo Therapeutics during the fourth quarter worth about $274,000. Finally, Hudson Bay Capital Management LP bought a new position in shares of Avalo Therapeutics during the fourth quarter worth about $305,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.